Startup profile · funding coverage
Freenome
AI-driven multi-cancer early detection from a routine blood draw.
Stage
growth
Status
private
Coverage
full
Why Freenome is interesting
Freenome is a high-stakes diagnostics AI company — clinical validation and FDA clearance are the whole game, with $590M+ raised including Roche strategic investment.
Key facts
- Series D (Dec 2021): $300M with Bain Capital Life Sciences (/fund/bain-capital-ventures) and a16z Life Sciences Growth Fund (/fund/andreessen-horowitz) (Freenome press)
- Roche invested $290M (Jan 2022) as strategic partner; Roche Venture Fund not in VCT directory
Investors in our directory
Funds linked from Freenome's profile — open a fund page for stage focus and related deal articles.
Industries
Healthtech Biotech & Life Sciences AI & Machine Learning
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
FAQs about Freenome
Funding context and why this company shows up in venture coverage.
Freenome builds AI-powered blood tests for multi-cancer early detection, combining genomic and proteomic signals with machine learning to screen for cancer before symptoms appear.
Freenome's $300M Series D (Dec 2021) included Andreessen Horowitz (/fund/andreessen-horowitz) and Bain Capital Ventures (/fund/bain-capital-ventures). Roche also invested $290M in Jan 2022 as a strategic partner.
Freenome is at Series D based on its December 2021 $300M round, with additional strategic investment from Roche in 2022.
Liquid biopsy for multi-cancer screening is one of the highest-stakes bets in healthtech — success requires both AI model accuracy and rigorous clinical trials. Freenome sits at that intersection.
No. Freenome remains a private company.
Last updated: 2026-07-24